October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
Ayurvedic herbs may reduce side effects and improve effectiveness of cancer treatments.
March 2024 in “Jurnal Ilmu Kesehatan Hewan” The treatment was effective for the puppy's skin and intestinal infections.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
February 2024 in “Buletin Veteriner Udayana” The dog with severe hair loss and itching improved after treatment for ehrlichiosis and demodicosis.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
Baricitinib may effectively treat oral lichen planus.
January 2024 in “Frontiers in immunology” Histone modification is key in treating chronic inflammatory skin diseases.
December 2023 in “Revista de la Facultad de Ciencias Médicas (Quito)” Fever and rash can be early signs of lupus.
October 2023 in “Dermatology practical & conceptual” Pulse corticosteroids help regrow hair in alopecia areata but have side effects, especially betamethasone.
May 2022 in “Gastroenterology” Targeting NETs may help reduce fibrosis in Crohn's disease.
March 2020 in “Central European Journal of Biology” The study found that stem cells and neutrophils are important for regenerating hair follicle structures in mice.
November 2019 in “Harper's Textbook of Pediatric Dermatology” Understanding normal hair growth and loss in children is key to diagnosing and treating hair disorders.
November 2019 in “Harper's Textbook of Pediatric Dermatology” The document is a detailed medical reference on skin and genetic disorders.
January 2019 in “Przegląd Dermatologiczny” Chemotherapy with docetaxel can cause painful nail and skin side effects that may lead to stopping treatment.
November 2018 in “The Journal of Allergy and Clinical Immunology: In Practice” Using old drugs for new uses can help treat rare immune deficiencies.
June 2018 in “Journal of Clinical Periodontology” Finasteride may cause gum problems, but stopping the drug can improve these issues.
March 2018 in “International journal of basic and clinical pharmacology” Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.
March 2017 in “Fundamental & Clinical Pharmacology” The model and estimator can predict drug exposure in kidney transplant patients well.
July 2016 in “American Journal of Dermatopathology” The meeting showcased rare skin disease cases, highlighting the need for accurate diagnosis and treatment.
February 2016 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” A new TP63 mutation was found in a baby with EEC syndrome, showing the need for TREC testing to check for immune issues.
The document tests knowledge and decision-making in hematology through multiple-choice questions.
The document provides 70 multiple choice questions to improve haematology skills.
January 2016 in “Springer eBooks” Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
January 2014 in “Side effects of drugs annual” Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.